We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks.
TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating. The update followed the company’s announcement of a non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant across up to two infectious disease areas. While BofA views the agreement and upfront payment as positive signs of interest in Novavax, Inc. (NASDAQ:NVAX)’s technology, the firm remains cautious about the timing of development for assets under the license and continues to rate the stock Underperform.
Additionally, on January 21, NVAX saw unusually strong bullish options activity, with call trading running at roughly three times normal levels. Implied volatility jumped by nearly eight points to above 71%, while the put/call ratio fell to 0.07, reflecting strong upside positioning ahead of the company’s expected earnings later in February.
Novavax, Inc. (NASDAQ:NVAX) is a U.S. biotechnology company developing and commercializing innovative vaccines against serious infectious diseases using its recombinant protein platform and Matrix‑M adjuvant. Its portfolio includes COVID‑19 vaccines and pipeline candidates for influenza and combo vaccines, supported by strategic partnerships to expand global health impact.
While we acknowledge the potential of NVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
